CymaBay Therapeutics (CBAY) News Today → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free CBAY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 6, 2024 | marketbeat.comVanguard Group Inc. Purchases 598,707 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Vanguard Group Inc. lifted its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 11.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 5,747,587 shares of the biopharmaceutical company's stock after acquiring an additional 598,7April 3, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Earns Sell Rating from Analysts at StockNews.comStockNews.com initiated coverage on CymaBay Therapeutics in a research note on Wednesday. They issued a "sell" rating on the stock.March 28, 2024 | marketbeat.comAssenagon Asset Management S.A. Invests $17.63 Million in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Assenagon Asset Management S.A. purchased a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 746,353 shares of the biopMarch 22, 2024 | za.investing.comGilead reduces 2024 earnings guidance after completing CymaBay takeoverMarch 22, 2024 | markets.businessinsider.comGilead Sciences Completes Acquisition Of CymaBay TherapeuticsMarch 22, 2024 | businesswire.comGilead Sciences Announces Completion of Acquisition of CymaBayMarch 22, 2024 | marketbeat.comTrading was temporarily halted for "CBAY" at 07:03 PM with a stated reason of "News pending."March 22, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Sold by Deutsche Bank AGDeutsche Bank AG cut its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 44.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 456,106 shares of the biopharmaceutical company's stock afterMarch 18, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Reaches New 52-Week High at $32.48CymaBay Therapeutics (NASDAQ:CBAY) Sets New 1-Year High at $32.48March 16, 2024 | finance.yahoo.comCBAY Jul 2024 34.000 callMarch 16, 2024 | finance.yahoo.comCBAY Apr 2024 31.000 putMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 33.000 callMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 29.000 putMarch 14, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Sees Significant Drop in Short InterestCymaBay Therapeutics, Inc. (NASDAQ:CBAY - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 29th, there was short interest totalling 5,850,000 shares, a drop of 30.1% from the February 14th total of 8,370,000 shares. Based on an average daily volume of 3,630,000 shares, the days-to-cover ratio is currently 1.6 days.March 11, 2024 | finance.yahoo.comInvesting in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gainMarch 10, 2024 | marketbeat.comGlenmede Trust Co. NA Buys Shares of 37,894 CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Glenmede Trust Co. NA bought a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 37,894 shares of the biopharmaceutical company's stock, valued at appMarch 9, 2024 | marketbeat.comSeven Eight Capital LP Purchases Shares of 41,556 CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Seven Eight Capital LP purchased a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,556 shares of the biopharmaceutiMarch 5, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Position Lessened by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. trimmed its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 6.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,125,000March 4, 2024 | globenewswire.comCymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary CholangitisMarch 1, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Sets New 1-Year High at $32.35CymaBay Therapeutics (NASDAQ:CBAY) Sets New 52-Week High at $32.35March 1, 2024 | marketbeat.com610,770 Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Acquired by MPM Bioimpact LLCMPM Bioimpact LLC bought a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 610,770 shares of the biopharmaceutical companMarch 1, 2024 | marketbeat.comHC Wainwright Equities Analysts Lower Earnings Estimates for CymaBay Therapeutics, Inc. (NASDAQ:CBAY)CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) - Investment analysts at HC Wainwright reduced their FY2028 earnings per share estimates for shares of CymaBay Therapeutics in a note issued to investors on Thursday, February 29th. HC Wainwright analyst E. Arce now anticipates that the biophFebruary 29, 2024 | markets.businessinsider.comMaintaining Hold on CymaBay Amid Gilead Acquisition Deal ClosureFebruary 29, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of CymaBay Therapeutics, Inc. (CBAY)February 29, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "neutral" rating and set a $32.50 price target on shares of CymaBay Therapeutics in a research note on Thursday.February 28, 2024 | marketwatch.comCymaBay Therapeutics 4Q Loss/Shr 35c >CBAYFebruary 28, 2024 | globenewswire.comCymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | marketbeat.comAlgert Global LLC Purchases New Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Algert Global LLC purchased a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 92,886 shares of the biopharmaceutical companFebruary 25, 2024 | marketbeat.comMonashee Investment Management LLC Acquires New Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)Monashee Investment Management LLC acquired a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 75,000 shares of the biopharmFebruary 24, 2024 | msn.comCymaBay Therapeutics (CBAY) Price Target Increased by 12.84% to 31.37February 23, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Purchased by Swiss National BankSwiss National Bank increased its stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 14.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 181,500 shares of the biopharmaceutical company's stock after purFebruary 22, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Stake Lessened by Deutsche Bank AGDeutsche Bank AG cut its holdings in CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 44.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 456,106 shares of the biopharmaceutical company's stock after selling 369,851 shares during the peFebruary 21, 2024 | finance.yahoo.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 21, 2024 | prnewswire.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 20, 2024 | msn.comLeerink Partners Downgrades CymaBay Therapeutics (CBAY)February 20, 2024 | globenewswire.comCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 20, 2024 | marketbeat.comClariVest Asset Management LLC Sells 63,600 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)ClariVest Asset Management LLC lowered its stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 39.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 96,481 shares of the biopharmFebruary 20, 2024 | marketbeat.comSVB Leerink Reaffirms Market Perform Rating for CymaBay Therapeutics (NASDAQ:CBAY)SVB Leerink restated a "market perform" rating and issued a $32.50 target price on shares of CymaBay Therapeutics in a research note on Tuesday.February 18, 2024 | marketbeat.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Acquired by New York State Common Retirement FundNew York State Common Retirement Fund lifted its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) by 39.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,4February 16, 2024 | businesswire.comCYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAYFebruary 15, 2024 | marketbeat.comFY2026 Earnings Forecast for CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Issued By HC WainwrightCymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) - Research analysts at HC Wainwright raised their FY2026 EPS estimates for CymaBay Therapeutics in a note issued to investors on Tuesday, February 13th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company will postFebruary 15, 2024 | finance.yahoo.comCBAY Jan 2026 37.000 callFebruary 14, 2024 | finance.yahoo.comCBAY Feb 2024 33.000 callFebruary 14, 2024 | finance.yahoo.comCBAY Jan 2025 8.000 putFebruary 14, 2024 | marketbeat.comAnalysts Offer Predictions for CymaBay Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:CBAY)CymaBay Therapeutics, Inc. (NASDAQ:CBAY - Free Report) - Equities researchers at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for CymaBay Therapeutics in a note issued to investors on Tuesday, February 13th. HC Wainwright analyst E. Arce forecasts that the biopharmaceuticaFebruary 14, 2024 | marketbeat.comAnalysts see over 50% gains in these 2 mid-cap biotech stocks (CBAY)The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.February 14, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Earns Market Perform Rating from Lifesci CapitalLifesci Capital reissued a "market perform" rating on shares of CymaBay Therapeutics in a report on Wednesday.February 13, 2024 | marketbeat.comCymaBay Therapeutics (NASDAQ:CBAY) Sees Strong Trading VolumeCymaBay Therapeutics (NASDAQ:CBAY) Sees Unusually-High Trading VolumeFebruary 13, 2024 | seekingalpha.comCymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver FranchiseFebruary 13, 2024 | marketbeat.comBTIG Research Reiterates Neutral Rating for CymaBay Therapeutics (NASDAQ:CBAY)BTIG Research reaffirmed a "neutral" rating on shares of CymaBay Therapeutics in a report on Tuesday. Get CymaBay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Bible Shocker: Have You Seen Elon Musk’s Miracle? (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process. Click here for the full story… CBAY Media Mentions By Week CBAY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CBAY News Sentiment▼0.000.42▲Average Medical News Sentiment CBAY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CBAY Articles This Week▼04▲CBAY Articles Average Week Get CymaBay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Summit Therapeutics News Crinetics Pharmaceuticals News Biohaven News Axsome Therapeutics News Insmed News Ultragenyx Pharmaceutical News Prestige Consumer Healthcare News HUTCHMED News Alkermes News Perrigo News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CBAY) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
